Home>>Peptides>>Diprotin A TFA (Ile-Pro-Pro (TFA))

Diprotin A TFA (Ile-Pro-Pro (TFA)) (Synonyms: Ile-Pro-Ile TFA)

Catalog No.GC31414

Diprotin A TFA (Ile-Pro-Pro (TFA)) (Ile-Pro-Ile TFA) is an inhibitor of dipeptidyl peptidase IV (DPP-IV).

Products are for research use only. Not for human use. We do not sell to patients.

Diprotin A TFA (Ile-Pro-Pro (TFA)) Chemical Structure

Cas No.: 209248-71-5

Size Price Stock Qty
5mg
$60.00
In stock
10mM (in 1mL Water)
$66.00
In stock
25mg
$193.00
In stock
50mg
$267.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Diprotin A (TFA) is an inhibitor of dipeptidyl peptidase IV (DPP-IV).

Diprotin A increases the phosphorylation of Src and vascular endothelial-cadherin (VE-cadherin) in human endothelial cells and disrupts endothelial cell-to-cell junctions, which are attenuated by CXCR4 (receptor of SDF-1α)-blocker or Src-inhibitor[1].

In the model of retinopathy of prematurity, Diprotin A increases not only retinal vascularity but also leakage. Additionally, in the murine diabetic retinopathy model, Diprotin A increases the phosphorylation of Src and VE-cadherin and aggravates vascular leakage in the retinas. Collectively, Diprotin A induces vascular leakage by augmenting the SDF-1α/CXCR4/Src/VE-cadherin signaling pathway[1].

[1]. Lee CS, et al. Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation. Sci Rep. 2016 Jul 6;6:29393.

Reviews

Review for Diprotin A TFA (Ile-Pro-Pro (TFA))

Average Rating: 5 ★★★★★ (Based on Reviews and 1 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Diprotin A TFA (Ile-Pro-Pro (TFA))

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.